To assess the stability and dynamics of MGMT methylation in recurrent gliomas and its influence on treatment decisions, particularly regarding temozolomide rechallenge.
Approach:
Patient Selection: Analyzed a cohort of 426 patients with paired MGMT methylation data from a molecular profiling database.
MGMT Assessment: Evaluated MGMT promoter methylation using pyrosequencing, categorizing results as hypermethylated, equivocal, or unmethylated.
Methylation Transition Groups: Defined four longitudinal methylation categories based on changes in status between two sampling points.
Data Analysis: Examined both categorical transitions and quantitative methylation percentages to understand biological changes.
Key Findings:
Approximately 70-85% concordance in MGMT methylation status between primary and recurrent gliomas.
A subset of tumors shows acquisition or loss of MGMT hypermethylation at recurrence.
Quantitative methylation dynamics may provide more insight than binary classifications.
Interpretation:
The study assesses the stability and dynamics of MGMT methylation in recurrent gliomas and its influence on treatment decisions.
Limitations:
The study relies on a proprietary database, which may limit generalizability.
Detailed longitudinal clinical data were not available for all patients.
Conclusion:
Reassessing MGMT methylation at recurrence could inform treatment strategies for recurrent gliomas.
by Henry Noren, Gabriella Pelofsky, Brianna Suffren, Laura Mittelman, Christine Yohn, Aminah Twyman, Christopher A. Febres-Aldana, Arevik Abramyan, Aparna Sertil, Randy S. D’Amico, Jonathan H. Sherman, Morana Vojnic
